OR WAIT 15 SECS
GE biopharma brands are now part of Cytiva, a Danaher Corporation Life Sciences company.
Cytiva is the new name of the former GE Healthcare Life Sciences biopharma business following its acquisition by Danaher Corporation, according to an April 1, 2020 announcement. The new company and name, which is now part of the Danaher Corporation Life Sciences platform, will be a $3.3-billion global life sciences company with nearly 7000 employees in 40 countries.
The Cytiva product portfolio will include instruments, consumables, and solutions for research, process development, manufacturing workflows. Brands include ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex, and Xuri.
“Our foundation of scientific expertise, our team, and our solid customer base place Cytiva in the right position to invest, develop, and accelerate growth in the industry. Our passion for helping bring life-changing therapies to patients is unwavering, and we will continue to introduce innovative technologies to the market which improve productivity for our customers,” Emmanuel Ligner, president of Cytiva, said in the April 1, 2020 press statement.
The company’s technologies are used in the development of biotherapies, including cell and gene therapies. The company reports that in 2019, more than 75% of the biological therapies approved by FDA used Cytiva’s technologies for manufacturing.
The company has facilities in Asia, Europe, and the Americas, and has centers for customer collaboration and training including the Testa Center in Uppsala, Sweden, and with the University of Technology at Sydney.
The company said it will continue to research collaborations, such as the center for advanced biological innovation and manufacturing in Boston with Harvard, MIT, teaching hospitals, and industry partners Fujifilm Diosynth Biotechnologies, and Alexandria Real Estate Equities, Inc.
The acquisition was announced in February 2019 and closed on March 31, 2020.
In a related matter, Sartorius announced on March 20, 2020 that the company received US and European regulatory approvals to acquire laboratory and bioprocessing technologies including businesses associated with single-use tangential flow filtration systems and stainless-steel hollow fiber tangential flow filtration systems. Sartorius had announced an agreement to purchase parts of Danaher’s Life Sciences portfolio in October 2019. The company is awaiting approval from authorities in China.